Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina

Represents First Regulatory Submission Outside of the United States

Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that Eurofarma Laboratórios has submitted a marketing authorization application for delafloxacin (marketed under the trade name Baxdela™ in the U.S.) in Argentina with the Ministry of Health’s National Administration of Drugs, Foods and Medical Technology (ANMAT). Eurofarma Laboratórios is Melinta’s commercialization and distribution partner for all countries in South and Central America and the Caribbean, including Argentina. The proposed indication for delafloxacin in Argentina is for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI).